Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Sadow

Showing results (181-190 of 243) with videos related to

Pageof 25
Sort By:
The Oncologist|March 1, 2011
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancerCarmelo Nucera, Matthew A Nehs, Sushruta S Nagarkatti, et al.
Surgery|November 20, 2012
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrenceJason D Prescott, Peter M Sadow, Richard A Hodin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2013
Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumorsWenlei He, John C Cheville, Peter M Sadow, et al.
Head & Neck|January 15, 2014
Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective reviewStacey T Gray, Marc W Herr, Rosh K V Sethi, et al.
BMC Systems Biology|April 7, 2019
Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithmsYangyang Hao, Quan-Yang Duh, Richard T Kloos, et al.
Endocrine-Related Cancer|August 25, 2012
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinomaRoberto Bellelli, Maria Domenica Castellone, Ginesa Garcia-Rostan, et al.
Thyroid : Official Journal of the American Thyroid Association|January 31, 2018
Circulating BRAF<sup>V600E</sup> Levels Correlate with Treatment in Patients with Thyroid CarcinomaCarrie C Lubitz, Tiannan Zhan, Viswanath Gunda, et al.
The New England Journal of Medicine|December 17, 2010
Case records of the Massachusetts General Hospital: Case 38-2010: a 13-year-old girl with an enlarging neck massRichard C Cabot, Nancy Lee Harris, Jo-Anne O Shepard, et al.
Head and Neck Pathology|May 29, 2026
Correction: Pleomorphic Adenoma with Epithelial Atypia, Apocrine Metaplasia, and/or In situ/Intracapsular Salivary Duct Carcinoma Are Indolent Lesions with Good Prognosis: A Proposal for Unified Nomenclature and Clinical ObservationGrayson G Cole, Matt Levin, David Ferber, et al.
The Journal of Experimental Medicine|June 20, 2012
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2Shavali Shaik, Carmelo Nucera, Hiroyuki Inuzuka, et al.
Pageof 25

Showing results (181-190 of 243) with videos related to

Sort By:
Pageof 25
The Oncologist|March 1, 2011
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancerCarmelo Nucera, Matthew A Nehs, Sushruta S Nagarkatti, et al.
Surgery|November 20, 2012
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrenceJason D Prescott, Peter M Sadow, Richard A Hodin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 20, 2013
Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumorsWenlei He, John C Cheville, Peter M Sadow, et al.
Head & Neck|January 15, 2014
Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective reviewStacey T Gray, Marc W Herr, Rosh K V Sethi, et al.
BMC Systems Biology|April 7, 2019
Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithmsYangyang Hao, Quan-Yang Duh, Richard T Kloos, et al.
Endocrine-Related Cancer|August 25, 2012
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinomaRoberto Bellelli, Maria Domenica Castellone, Ginesa Garcia-Rostan, et al.
Thyroid : Official Journal of the American Thyroid Association|January 31, 2018
Circulating BRAF<sup>V600E</sup> Levels Correlate with Treatment in Patients with Thyroid CarcinomaCarrie C Lubitz, Tiannan Zhan, Viswanath Gunda, et al.
The New England Journal of Medicine|December 17, 2010
Case records of the Massachusetts General Hospital: Case 38-2010: a 13-year-old girl with an enlarging neck massRichard C Cabot, Nancy Lee Harris, Jo-Anne O Shepard, et al.
Head and Neck Pathology|May 29, 2026
Correction: Pleomorphic Adenoma with Epithelial Atypia, Apocrine Metaplasia, and/or In situ/Intracapsular Salivary Duct Carcinoma Are Indolent Lesions with Good Prognosis: A Proposal for Unified Nomenclature and Clinical ObservationGrayson G Cole, Matt Levin, David Ferber, et al.
The Journal of Experimental Medicine|June 20, 2012
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2Shavali Shaik, Carmelo Nucera, Hiroyuki Inuzuka, et al.
Pageof 25